– Financing led by Commodore Capital with participation from new and existing biotech focused investors – – Alto expects to use the proceeds of the financing to...
– Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – ...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the...
– The review provides strong scientific rationale to support Alto’s drug development approach leveraging its Precision Psychiatry Platform –
– Issued and pending claims expected to protect ALTO-207 into the mid-2040s –
– Data presented demonstrate robust validation of Theta ITC as an EEG biomarker of CIAS and support its use as the primary outcome in the ongoing Phase 2 POC study of ALTO-101 – ...
– Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression; on track to initiate Phase 2b trial in the first half of 2026 and Phase 3 trial by early 2027 – ...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...